Cancer nanomedicine: progress, challenges and opportunities
By Jinjun Shi, P. Kantoff, R. Wooster, O. Farokhzad. Nature Reviews. Cancer, 2016
4,910 citations recorded by the source corpus.
The intrinsic limits of conventional cancer therapies prompted the development and application of various nanotechnologies for more effective and safer cancer treatment, herein referred to as cancer nanomedicine. Considerable technological success has been achieved in this field, but the main obstacles to nanomedicine becoming a new paradigm in cancer therapy stem from the complexities and heterogeneity of tumour biology, an incomplete understanding of nano–bio interactions and the challenges regarding chemistry, manufacturing and controls required for clinical translation and commercialization. This Review highlights the progress, challenges and opportunities in cancer nanomedicine and discusses novel engineering approaches that capitalize on our growing understanding of tumour biology and nano–bio interactions to develop more effective nanotherapeutics for cancer patients.
Subfields: Biomaterials, Biomedical Engineering
View Paper: https://www.semanticscholar.org/paper/f4da328be0fcbfaf507144b7a67952ae4184ffe0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomaterials
In Biomedical Engineering
Citations in the corpus
- Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination (2018, positive): “2,7,8 This work establishes a simple and robust nanosca ff old, suitable for modular multi-merization of complex proteins just by mixing.”
- Innovative approaches for cancer treatment: current perspectives and new challenges (2019, background): “Furthermore, nanoparticles can be engineered to be extremely selective for a precise target [21, 22] (see the “Targeted therapy and immunotherapy” section) and to release the drug in a controlled way by responding to a specific stimulus [18, 23–25].”
- Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization (2018, background): “Despite the arsenal of nanoparticulate targeted systems currently under preclinical development or in clinical trials, it is indisputable that liposomes are dominant on the NNM market (Table 1) and were the first FDA-approved NNM (Caster et al., 2017; Shi et al., 2017).”